185 related articles for article (PubMed ID: 11809678)
1. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Bennett PF; Craig BA; Glickman NW; Mutsaers AJ; Snyder PW; Widmer WR; DeGortari AE; Bonney PL; Knapp DW
Cancer Res; 2002 Jan; 62(2):356-8. PubMed ID: 11809678
[TBL] [Abstract][Full Text] [Related]
2. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment tumor prostaglandin E2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy.
Mutsaers AJ; Mohammed SI; DeNicola DB; Snyder PW; Glickman NW; Bennett PF; de Gortari AE; Bonney PL; Knapp DW
Prostaglandins Leukot Essent Fatty Acids; 2005 Mar; 72(3):181-6. PubMed ID: 15664302
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
Sennlaub F; Valamanesh F; Vazquez-Tello A; El-Asrar AM; Checchin D; Brault S; Gobeil F; Beauchamp MH; Mwaikambo B; Courtois Y; Geboes K; Varma DR; Lachapelle P; Ong H; Behar-Cohen F; Chemtob S
Circulation; 2003 Jul; 108(2):198-204. PubMed ID: 12821538
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma.
Li G; Yang T; Li L; Yan J; Zeng Y; Yu J; Zhang Y
Colloids Surf B Biointerfaces; 2004 Aug; 37(1-2):15-9. PubMed ID: 15450303
[TBL] [Abstract][Full Text] [Related]
9. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Eibl G; Takata Y; Boros LG; Liu J; Okada Y; Reber HA; Hines OJ
Cancer Res; 2005 Feb; 65(3):982-90. PubMed ID: 15705899
[TBL] [Abstract][Full Text] [Related]
10. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
11. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
Seno H; Oshima M; Ishikawa TO; Oshima H; Takaku K; Chiba T; Narumiya S; Taketo MM
Cancer Res; 2002 Jan; 62(2):506-11. PubMed ID: 11809702
[TBL] [Abstract][Full Text] [Related]
13. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma.
Leung WK; To KF; Go MY; Chan KK; Chan FK; Ng EK; Chung SC; Sung JJ
Int J Oncol; 2003 Nov; 23(5):1317-22. PubMed ID: 14532971
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
18. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
19. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
20. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
